News & Updates

The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.

Among nursing home residents, rather than using a one-size-fits-all threshold temperature, looking at individual changes in body temperature and temperature variability, could lead to better prediction of COVID-19 infection, a recent study has found.

Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.

In patients with remitted major depressive disorder (MDD), the use of psychological relapse prevention interventions, whether as a standalone or in combination with medication, effectively reduces the risk of relapse/recurrence, according to a recent meta-analysis.

Among the biochemical indices of obesity, cholesterol, creatinine, and platelet count appear to correlate with myocardial infarction or angina pectoris in both men and women, reports a recent study. Other indicators, including anthropometric measures, varied between sexes.

The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.

Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.